Surmodics, Inc.

NasdaqGS:SRDX Voorraadrapport

Marktkapitalisatie: US$536.9m

Surmodics Beheer

Beheer criteriumcontroles 2/4

De CEO Surmodics is Gary Maharaj, benoemd in Dec2010, heeft een ambtstermijn van 13.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.53M, bestaande uit 18.2% salaris en 81.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.42% van de aandelen van het bedrijf, ter waarde $ 7.62M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.5 jaar en 13.9 jaar.

Belangrijke informatie

Gary Maharaj

Algemeen directeur

US$3.5m

Totale compensatie

Percentage CEO-salaris18.2%
Dienstverband CEO13.9yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn6.5yrs
Gemiddelde ambtstermijn bestuur13.9yrs

Recente managementupdates

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03
Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 30
Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

May 02
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Sep 17
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26
News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22
An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14
Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17
Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03
Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08
Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22
Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03
Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04
Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24
Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Analyse CEO-vergoeding

Hoe is Gary Maharaj's beloning veranderd ten opzichte van Surmodics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

US$14m

Dec 31 2023n/an/a

US$6m

Sep 30 2023US$4mUS$640k

-US$2m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$36m

Dec 31 2022n/an/a

-US$32m

Sep 30 2022US$3mUS$620k

-US$27m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021n/an/a

US$2m

Sep 30 2021US$3mUS$602k

US$4m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

US$7m

Dec 31 2020n/an/a

US$701k

Sep 30 2020US$3mUS$585k

US$1m

Jun 30 2020n/an/a

US$8m

Mar 31 2020n/an/a

US$7m

Dec 31 2019n/an/a

US$6m

Sep 30 2019US$2mUS$568k

US$8m

Jun 30 2019n/an/a

US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018n/an/a

-US$2m

Sep 30 2018US$2mUS$551k

-US$4m

Compensatie versus markt: De totale vergoeding ($USD 3.53M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.


CEO

Gary Maharaj (61 yo)

13.9yrs

Tenure

US$3,527,263

Compensatie

Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Gary Maharaj
CEO, President & Director13.9yrsUS$3.53m1.42%
$ 7.6m
Timothy Arens
Senior VP of Finance & Information Technology and CFO6.5yrsUS$1.30m0.54%
$ 2.9m
Gordon Weber
Senior VP of Legal4.5yrsUS$1.10m0.16%
$ 842.5k
Charles Olson
Senior VP & President of Medical Device Coatings20.1yrsUS$1.12m0.38%
$ 2.1m
Teryl L. Sides
Senior VP & President of Vascular Interventions2.5yrsUS$1.49m0.26%
$ 1.4m
John Manders
Corporate Controller6.5yrsgeen gegevens0.058%
$ 313.0k
Joel Suiter
Director of Corporate Developmentno datageen gegevensgeen gegevens
Joseph Stich
Senior VP of Human Resources & President of In Vitro Diagnostics4.6yrsUS$970.92k0.45%
$ 2.4m

6.5yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SRDX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Gary Maharaj
CEO, President & Director13.9yrsUS$3.53m1.42%
$ 7.6m
Ronald Kalich
Independent Director10.8yrsUS$186.50k0.26%
$ 1.4m
David Dantzker
Independent Director13.8yrsUS$185.00k0.27%
$ 1.4m
Susan Knight
Independent Non-Executive Chair of the Board16.8yrsUS$229.00k0.23%
$ 1.2m
José Bedoya
Independent Director22.8yrsUS$176.50k0.20%
$ 1.1m
Lisa Heine
Independent Director7.6yrsUS$176.50k0.088%
$ 472.3k

13.9yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SRDX zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).